Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - first-line


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.371
Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.

Angel Alsina · Masatoshi Kudo · Arndt Vogel · Ann-Lii Cheng · Won Young Tak · Baek-Yeol Ryoo · T. R. Jeffry Evans · Carlos López-López · Bruno Daniele · Soamnauth Misir · Min Ren · Namiki Izumi · Shukui Qin · Richard S. Finn ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.388
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

Arlene Odelia Siefker-Radtke · Mayer Fishman · Arjun Vasant Balar · Giovanni Grignani · Adi Diab · Jianjun Gao · Mary Tagliaferri · Alison L. Hannah · Erin E. Karski · Jonathan Zalevsky · Ute Hoch · Ahsan Naqi Rizwan · Mehmet Asim Bilen ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.584
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Shaan Dudani · Jeffrey Graham · Connor Wells · Sumanta K. Pal · Nazli Dizman · Frede Donskov · Georg A. Bjarnason · Aaron Richard Hansen · Marco Adelmo James Iafolla · Ulka N. Vaishampayan · Camillo Porta · Benoit Beuselinck · Flora Yan · Lori Wood · Elizabeth Chien Hern Liow · Christian Kollmannsberger · Takeshi Yuasa · Chiyuan A Zhang · Toni K. Choueiri · Daniel Yick Chin Heng ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.363
Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.

Petros Grivas · François Laliberté · Yunes Doleh · Cristi O’Connor · Mei Sheng Duh · Rahul Shenolikar ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.555
Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.

Shingo Hatakeyama · Toshiaki Tanaka · Yoshinori Ikehata · Naoki Fujita · Naoya Masumori · Hiroshi Kitamura · Takahiro Yoneyama · Yasuhiro Hashimoto · Chikara Ohyama ·

Medicine
PDF

Highly Related Keywords from first-line

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals